Pre-registration is now closed. We welcome you to register on-site by coming to McCormick Place West, Skyline Ballroom, W375b (Level 3). Remember to bring your AUA badge to expedite your registration.
5:30 PM Registration and Dinner
6:00 PM Welcome and Introduction – Charles J. Ryan, MD
6:10 PM Practical Guidance on the Clinical Role of BRCA and Other DNA Damage Repair Genes in Prostate Cancer – David A. Quigley, PhD
6:40 PM Genetic Testing in Prostate Cancer for the Clinician – Todd M. Morgan, MD
7:10 PM Targeting DNA Repair Defects in Prostate Cancer: The Role of PARP Inhibitors – Charles J. Ryan, MD
7:40 PM Applying the Data to Practice: Panel Discussion of Cases and Audience Question and Answer Session
Date / Time
Charles Ryan, MD
Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
Todd Morgan, MD
Department of Urology
University of Michigan
Ann Arbor, Michigan
David Quigley, PhD/ND/EdD
Assistant Adjunct Professor
Department of Epidemiology and Biostatistics
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California
The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating PARP inhibitors into the treatment of patients with prostate cancer.
This program is intended for oncologists and urologists and other healthcare providers who care for patients with prostate cancer.
- Describe the rationale and process for assessing germline and somatic DNA repair pathway alterations in prostate cancer
- Examine the mechanism of PARP inhibition to achieve “synthetic lethality” in prostate cancer with deficient DNA damage response
- Evaluate the available clinical evidence for the use of PARP inhibitors to treat metastatic CRPC harboring BRCA1/2 or other DNA damage response mutations
- Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitor monotherapy or in combination with other agents in prostate cancer
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Designation of Credit
Physician Continuing Education
CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.